<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND AIMS: The macrophage inhibitory cytokine-1 (MIC-1) is a divergent member of the transforming growth factor-β (TGF-β) superfamily that can serve as a potential immune-therapeutic target and/or a prognostic biomarker for the treatment of some <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This article reviews the current published data on the molecular and clinical application of MIC-1 in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Literature review was conducted using Medline, PubMed, Embase and Cochrane databases </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: MIC-1 is the only known secreted p53-regulated cytokine and therefore can serve as a biomarker for p53 activation both in vitro and in vivo </plain></SENT>
<SENT sid="4" pm="."><plain>MIC-1 gene can be activated by <z:chebi fb="0" ids="35544">cyclooxygenase inhibitors</z:chebi> and has pro-apoptotic and anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> activities </plain></SENT>
<SENT sid="5" pm="."><plain>Although MIC-1 may induce anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> role in the early stages of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, it can promote the invasiveness and metastatic behaviour in advanced stages </plain></SENT>
<SENT sid="6" pm="."><plain>Greater concentration of MIC-1 was associated with the induction of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0002039'>anorexia</z:hpo> and <z:hpo ids='HP_0001824'>weight loss</z:hpo> in animals and humans </plain></SENT>
<SENT sid="7" pm="."><plain>Of clinical interest, MIC-1 out-performs <z:hpo ids='HP_0000001'>all</z:hpo> available biomarkers including CA19-9 in the differentiation of patients with resectable <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> from patients with benign <z:e sem="disease" ids="C0030286" disease_type="Disease or Syndrome" abbrv="">pancreatic disease</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>MIC-1 gene was over-expressed in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), and a progressive rise of MIC-1 serum levels was noted in patients with <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> and further in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: MIC-1 cytokine has the potential characteristics for a new diagnostic biomarker and a target for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment </plain></SENT>
<SENT sid="10" pm="."><plain>Further research however is required to characterise MIC-1 receptors and to revalidate its diagnostic power in larger and better-standardised clinical studies </plain></SENT>
</text></document>